Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco
28 tablet
Sofosbuvir 400mg + Daclatasvir 60mg
Keep in cold place
Delivering To:
Overview
Hepcinat Plus 60mg/400mg Tablet is an antiviral medication, which is used in combination with other medicines. It is used in the treatment of chronic hepatitis C virus (HCV) infection. It stops or prevents the growth of viruses in the body and helps remove the virus from the blood. Hepcinat Plus 60mg/400mg Tablet helps you to recover faster and control the infection from spreading in your body. This is a prescription-based medicine, which is to be taken only when prescribed by your doctor.
Hepatitis C
Treatment of Chronic hepatitis C virus (HCV) infection
The human body reacts differently to Hepcinat Plus 60mg/400mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Hepcinat Plus 60mg/400mg Tablet are mentioned below:
Headache
Fever
Chills
Nausea
Insomnia (difficulty in sleeping)
Tiredness
Loss of appetite
Fatigue Anemia (low number of red blood cells)
Skin rash
Itching
Irritability
Take the dose of Hepcinat Plus 60mg/400mg Tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Hepcinat Plus 60mg/400mg Tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.
Hepcinat Plus 60mg/400mg Tablet is made by combining two medicines that are Sofosbuvir and Daclatasvir. They both lower the viral load in the body and the viruses in the blood. Daclatasvir inhibits a protein called NS5A, which is an important protein required for the replication of the hepatitis C virus, whereas Sofosbuvir inhibits the NS5B protein, which is also an essential protein in the replication of the hepatitis C virus. Hepcinat Plus 60mg/400mg Tablet is a direct-acting antiviral medication that is used to increase the effectiveness in treating HCV.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Hepcinat Plus 60mg/400mg Tablet. Consult your doctor for further information.
Pregnancy
consult your doctor
Hepcinat Plus 60mg/400mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking Hepcinat Plus 60mg/400mg Tablet during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
consult your doctor
Hepcinat Plus 60mg/400mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor before taking Hepcinat Plus 60mg/400mg Tablet while breastfeeding, as there are chances that it may pass to the developing baby through the breast milk of the mother.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking Hepcinat Plus 60mg/400mg Tablet, as you may feel dizzy.
Kidney
caution
Share your medical history with your healthcare expert in case of kidney disease before taking Hepcinat Plus 60mg/400mg Tablet. Patients with renal impairment must be careful while taking Hepcinat Plus 60mg/400mg Tablet. They may require adjustment in the dose.
Liver
caution
Inform your doctor before starting Hepcinat Plus 60mg/400mg Tablet if you have liver disease to avoid any serious side effects. Patients with hepatic impairment must be careful while taking Hepcinat Plus 60mg/400mg Tablet. They may require adjustment in the dose.
It is advisable not to miss a dose of Sofosbuvir And Daclatasvir tablets. If you miss a scheduled dose of this medicine, contact your doctor immediately.
Hepcinat plus 60mg/400mg tablet is an antiviral medication, used along with other medications, in the treatment of chronic Hepatitis C Virus (HCV) infection in adults.
Take the Hepcinat Plus 60mg/400mg tablet exactly as your healthcare provider tells you. Do not alter the dose strength on your own. Do not crush, chew, or break the tablet.
Avoid the consumption of fatty or sugary foods and alcohol.
Side effects of Hepcinat Plus 60mg/400mg tablets are fever, nausea, anemia, insomnia, chills, muscle pain, cramps, fainting, and skin rash. If you experience these or any other side effects, make sure to consult your healthcare provider for the same.
Do not drive or operate heavy machines if you feel unwell after taking this medicine.
If you miss a dose of Hepcinat Plus 60mg/400mg tablet, take it as soon as you remember. Do take an extra dose of the medicine to make up for the missed one.
It is important to complete the full course of the Hepcinat Plus 60mg/400mg tablet as prescribed by the doctor. If you feel better, then you should also not stop taking Hepcinat tablet as it may worsen your symptoms.
Time may vary from individual to individual, depending on the severity and stage of the disease. But it is essential to complete the full course of the Hepcinat Plus 60mg/400mg tablet.
Consult your doctor before taking any supplements or vitamins to prevent any kind of interactions with Hepcinat plus 60mg/400mg tablet, which can cause severe effects to the individual.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Butt Z, Shah SMA. (2024). Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in the Pakistani population - A real-world experience. Pak J Med Sci. 35(2):409-413.
Kapoor R., Kohli A., Sidharthan S. (2024). All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID Synergy Trial. Hepatology. 4(60).
Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, Malhotra A, Parvez A, Sood A. (2023). Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3, and 4: A Real-Life Experience from India. J Clin Exp Hepatol. 8(1):7-14.
Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. (2024). Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther. 22(3):225-236.
Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH. (2023). Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int. 12(4):339-347.
Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J. (2024). Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. Clin Ther. 38(2):404-12.
Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. (2024).Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C-Related Decompensated Cirrhosis. J Clin Exp Hepatol. 9(1):4-12.
Natco
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.